Skip to main content

Table 3 Toxicity, dose reduction and reasons for therapy discontinuation (n = 119)

From: Preference of elderly patients’ to oral or intravenous chemotherapy in heavily pre-treated recurrent ovarian cancer: final results of a prospective multicenter trial

Parameter i.v., n = 102 (%) Oral, n = 17 (%)
Toxicity (grade 3 or 4) 742 AE’s a 14 AE’s
Haematological (all grade)
 Thrombocytopenia 38.6 30
 Leucopenia 27.3 50
 Neutropenia 16.3 10
 Anemia 11.6 10
 Febrile Neutropenia 7 -
Non-haematological (all grade)
 Ascites 9.9 11
 Subileus (severe constipation) 8.6 11
 Constipation 6.2 -
 Abdominal pain 4.9 11
 Ileus (bowel obstruction) 4.9 -
 Vomiting 4.9 -
 Nausea 3.7 -
 Diarrhoea 2.5 11
 Rectal incontinence 2.5 -
 Others (< 1%) 51.8 56
Dose reduction (27 of all 421 cycles) 6.4
 (26 of 376 i.v. cycles vs. 1 of 45 oral cycles) 6.9 2.2
Prolongation of treatment interval (> 14d) 25 4.4
Reasons for early therapy discontinuation
 Progressive disease 42 47.1
 Patients preference 15.7 11.8
 Other reasons 15.7 11.8
 Haematological toxicity (grade 3/4) 11.8 -
 Dead of tumour 5.9 11.8
 Non-haematological toxicity (grade 3/4) 2.9 11.8
 Concomitant disease 2.9 5.9
 Complete remission 1 -
Main cause of death
 Tumour related 80.4 82.4
 Others 7.8 5.9
  1. aadverse events